Clinical Trial Update: Study of Protease Inhibitor Regimen Switch in HIV-1 Infected Patients With Undetectable Viral Load to Prove the Non-inferiority of Once Daily Dose Regimen Versus the Current Twice Daily Regimen to Maintain the Viral Load Under the Limit of Detection. [Phase 3]

View source ↗

Summary

A Phase 3 randomized trial evaluating whether a once-daily protease inhibitor regimen is non-inferior to the current twice-daily regimen in HIV-1 infected patie…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Snippet

Sponsor: Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida | Conditions: HIV-1 Infection, HIV Infections | Phase 3 | Status: COMPLETED